SEPN Septerna, Inc. Common Stock
XNAS 49.74 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SEPN
$49.74
—
What changed
Recent filings, trades and movesKey stats
$49.74
- 52-Week Range
- $17.98 – $51.10
- YTD
- +77.77%
- IV Rank (30D)
- 35.89
- Straddle Price
- $9.95
- P/C Vol Ratio
- 0.48
- Market Cap
- $2.3B
- Open
- $49.86
- Day Range
- $48.07 – $50.06
- Volume
- 358,966
- Prev Close
- $48.85
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.61 |
| Cost of Equity (CAPM) | 13.76% (VRP-adj) |
| WACC | 14.10% |
| Volatility Risk Premium | +44.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +24.4% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | -6.3% |
| Book / Price | 17.6% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 106.3% |
| Debt / Equity | 0.00 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +17.3% (reverse-DCF on current price) |
| SMA 50 | $39.52 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $41.59 |
| Bollinger Width / SMA20 | 38.2% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $2B |
Peers used for multiples: JNJ, LLY, MANE, RPRX, SUPN, VTRS, XERS, ZTS
60-Day Conviction
86%
20-Day Fair Value
≈ by Dec 8, 2026
$50.58
α +2.1%
rank 56%
conviction
93%
40-Day Fair Value
≈ by Jan 6, 2027
$51.42
α +3.8%
rank 54%
conviction
89%
60-Day Fair Value
≈ by Feb 4, 2027
$51.79
α +4.6%
rank 56%
conviction
86%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $72.31 | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 42.4× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 20.6× · 7 peers |
| Peer P/B | $53.41 | 22% | median 6.2× · 6 peers |
| Peer P/S | $15.94 | 22% | median 6.6× · 7 peers |
| Market Anchor (SMA50) | $39.52 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $50.44 | 56% | 23 strikes · skew -0.02 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.3B
- Employees
- 130
- List Date
- 2024-10-25
- CIK
- 0001984086
- Next Earnings
- 2026-11-09 (After-Close)
- EPS Forecast
- ($0.41)
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.septerna.com
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -20.80% | -16.58% | -18.69% |
| Feb | -- | -58.55% | 15.94% | -21.30% |
| Mar | -- | -4.46% | -16.10% | -10.28% |
| Apr | -- | 38.65% | -2.50% | 18.07% |
| May | -- | 29.55% | 27.91% | 28.73% |
| Jun | -- | 6.45% | 11.71% | 9.08% |
| Jul | -- | 17.08% | -1.12% | 7.98% |
| Aug | -- | -0.90% | 9.06% | 4.08% |
| Sep | -- | 52.43% | 3.85% | 28.14% |
| Oct | 6.92% | 8.42% | 15.64% | 10.33% |
| Nov | 16.06% | 44.74% | 14.65%* | 25.15% |
| Dec | -7.51% | 0.94% | -- | -3.29% |
| Total | 14.77% | 68.01% | 67.85% | 50.21% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $42.19
SMA 50: $39.73
SMA 200: $32.69
Current: $49.51
EMA 12: $45.29
EMA 26: $42.69
MACD: 2.6004 | Signal: 0.7915
BULLISH
ADX (14): 17.88
RANGE
+DI: 29.34
−DI: 13.16
Momentum Oscillators
RSI (14): 73.77
OVERBOUGHT
Stoch %K: 88.60
Stoch %D: 90.36
Williams %R: -12.17
Volume & Volatility
BB Upper: $50.61
BB Lower: $33.77
NEUTRAL
OBV: 35,431,182
Vol SMA 20: 347,217
Vol ROC: 27.81%
ATR: $2.57
True Range: $1.99
HV 20: 54.7%
HV 30: 52.9%
HV 60: 48.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All SEPN news →
Earnings History
6 of 7 under expected move
Avg Expected Move
34.10%
Avg Actual Move
6.30%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-03-27 | After-Close | 151.19% | 3.02% | 0.02x | Within |
| 2025-05-15 | Pre-Market | 14.76% | 0.39% | 0.03x | Within |
| 2025-08-11 | After-Close | 21.32% | 2.52% | 0.12x | Within |
| 2025-11-10 | After-Close | 14.92% | 6.30% | 0.42x | Within |
| 2026-03-09 | After-Close | 9.98% | 3.58% | 0.36x | Within |
| 2026-05-11 | After-Close | 11.67% | 5.39% | 0.46x | Within |
| 2026-08-10 | After-Close | 14.86% | 22.93% | 1.54x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
SEPN Options Activity & IV Rank
SEPN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 79.5%
7-DTE IV: 101.7%
Expected Move: $9.95
7-DTE Move: $6.92
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 230
Put Volume: 110
P/C Volume: 0.478
BULLISH
Call OI: 1,378
Put OI: 1,041
P/C OI: 0.755
Total OI: 2,419
ATM Options Pricing
ATM Call: $4.70
ATM Put: $5.25
Call %: 9.4%
Put %: 10.6%
Chain Summary
Chain Volume: 340
Chain OI: 2,419
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 76th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
76%
vs own history
GEX tilt
+0.86
OI-weighted, today
Vanna tilt
+0.44
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +0.44: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)24.7LowNov 9
IV Rank (30 DTE)35.9MediumNov 9
Straddle Price (30 DTE)$9.95Nov 9
Beta Analysis
Risk Metrics
Beta: 0.9787
Alpha: 108.55%
Correlation: 0.1993
R-Squared: 4.0%
Stock Volatility: 67.6%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own SEPN
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $1.7M | #2659 of 3716 | -59.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.4M | #2164 of 3138 | +9.9% | 13F | |
| Citadel Hedge fund Ken Griffin | $213K | #5431 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SEPN Institutional Ownership (13F)
Filings for 2026-06-30 · 41 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 44,682,412 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$34.88M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $14.74M | 42.24% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $8.77M | 25.15% | 2026-06-30 |
| 3 | TUDOR INVESTMENT CORP ET AL | $6.70M | 19.20% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $2.74M | 7.85% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $1.92M | 5.49% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $19.57K | 0.06% | 2026-09-30 |
5 filers$13.20M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $6.70M | 50.74% | 2026-06-30 |
| 2 | TUDOR INVESTMENT CORP ET AL | $3.35M | 25.37% | 2026-06-30 |
| 3 | DIADEMA PARTNERS LP | $2.00M | 15.15% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $1.14M | 8.60% | 2026-06-30 |
| 5 | Persistent Asset Partners Ltd | $18.21K | 0.14% | 2026-06-30 |
SEPN Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Elizabeth Bhatt | President and COO | Mixed Exer +4,000 · Sell −4,000 |
— | $22.11 | -$122.4K | EDGAR |
| 2026-09-10 | Rajiv Patni | Chief Medical Officer | Grant (A) | +275,000 opt | — | EDGAR | |
| 2026-09-03 | Daniel D. Long | SVP, Drug Discovery | Mixed Sell −3,333 · Exer +3,333 |
— | $20.29 | -$116.9K | EDGAR |
| 2026-08-14 | RA Capital Nexus Fund III, L.P. | Director | Sell (S) | −1,493,000 | $42.50 | -$63.45M | EDGAR |
| 2026-08-14 | Third Rock Ventures V, L.P. | 10%+ Owner | Sell (S) | +147,200 | $50.27 | $7.40M | EDGAR |
| 2026-08-13 | Elizabeth Bhatt | President and COO | Mixed Sell −25,000 · Exer +25,000 |
— | $24.89 | -$955.3K | EDGAR |
| 2026-08-05 | Daniel D. Long | SVP, Drug Discovery | Mixed Sell −3,334 · Exer +3,334 |
— | $18.61 | -$105.7K | EDGAR |
| 2026-07-17 | Elizabeth Bhatt | President and COO | Mixed Exer +4,000 · Sell −4,000 |
— | $20.40 | -$108.7K | EDGAR |
| 2026-07-02 | Daniel D. Long | SVP, Drug Discovery | Mixed Exer +3,333 · Sell −3,333 |
— | $18.56 | -$105.3K | EDGAR |
| 2026-06-24 | Daniel D. Long | SVP, Drug Discovery | Mixed Sell −15,000 · Exer +15,000 |
— | $20.47 | -$451.2K | EDGAR |
| 2026-06-16 | Samira Shaikhly | Chief People Officer | Mixed Exer +6,250 · Sell −6,250 |
— | $23.39 | -$146.1K | EDGAR |
| 2026-06-03 | Samira Shaikhly | Chief People Officer | Mixed Exer +5,935 · Sell −5,935 |
— | $15.40 | -$160.6K | EDGAR |
| 2026-05-28 | Samira Shaikhly | Chief People Officer | Mixed Exer +11,798 · Sell −11,798 |
— | $18.44 | -$274.3K | EDGAR |
| 2026-04-17 | Elizabeth Bhatt | President and COO | Mixed Exer +4,000 · Sell −4,000 |
— | $15.57 | -$70.1K | EDGAR |
| 2026-03-04 | Samira Shaikhly | Chief People Officer | Mixed Exer +70,453 · Sell −70,453 |
— | $14.97 | -$1.85M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SEPN Insider Holdings
9 insiders · @ $49.51
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Third Rock Ventures V, L.P. | 10%+ Owner | 10,280,191 | $508.97M | $25.38M | 4 | 2026-08-14 |
| 2 | RA Capital Nexus Fund III, L.P. | Director | 4,777,415 | $236.53M | -$63.45M | 1 | 2026-08-14 |
| 3 | Jeffrey Finer | Chief Executive Officer | 821,907 | $40.69M | $97.0K | 4 | 2026-02-10 |
| 4 | Elizabeth Bhatt | President and COO | 174,209 | $8.63M | -$1.60M | 7 | 2026-10-19 |
| 5 | Uwe Klein | SVP, Biological Sciences | 127,533 | $6.31M | $0 | 3 | 2026-02-10 |
| 6 | Alan Ezekowitz | Director | 117,420 | $5.81M | $608.2K | 3 | 2025-06-20 |
| 7 | Daniel D. Long | SVP, Drug Discovery | 99,745 | $4.94M | -$951.3K | 7 | 2026-09-03 |
| 8 | Gil M Labrucherie | Chief Financial Officer | 40,000 | $1.98M | $229.2K | 5 | 2026-02-10 |
| 9 | Samira Shaikhly | Chief People Officer | 793 | $39.3K | -$2.73M | 6 | 2026-06-16 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SEPN Board & Officers
As of SEC filings through Oct 19, 2026Directors 13
- Abraham Bassan · since Oct 24, 2024
- Alan Ezekowitz · since Oct 24, 2024
- Bernard Coulie · since Oct 24, 2024
- Jake Simson · since Oct 24, 2024
- Jeffrey Finer · since Oct 24, 2024
- Jeffrey K Tong · since Oct 24, 2024
- Peter Kolchinsky · since Oct 24, 2024
- RA Capital Healthcare Fund LP (entity) · since Oct 24, 2024
- RA Capital Nexus Fund III, L.P. (entity) · since Oct 24, 2024
- Ra Capital Management, L.p. (entity) · since Oct 24, 2024
- Rajeev M. Shah · since Oct 24, 2024
- Shalini Sharp · since Oct 24, 2024
- Keith Michael Gottesdiener · since Sep 25, 2025
Officers 9
- Jeffrey Finer · Chief Executive Officer · listed since Aug 2025
- Elizabeth Bhatt · President and COO · listed since Aug 2025
- Gil M Labrucherie · Chief Financial Officer · since Jan 6, 2025
- Jae B. Kim · Chief Medical Officer · since Oct 24, 2024
- Samira Shaikhly · Chief People Officer · since Oct 24, 2024
- Mark Andrew Wilson · Chief Legal Officer · since Jan 5, 2026
- Rajiv Patni · Chief Medical Officer · since Aug 24, 2026
- Daniel D. Long · SVP, Drug Discovery · since Oct 24, 2024
- Uwe Klein · SVP, Biological Sciences · since Oct 24, 2024
10% owners 10
- Peter Kolchinsky · since Oct 24, 2024
- RA Capital Healthcare Fund LP (entity) · since Oct 24, 2024
- Ra Capital Management, L.p. (entity) · since Oct 24, 2024
- Rajeev M. Shah · since Oct 24, 2024
- Third Rock Ventures GP V, LP (entity) · since Oct 24, 2024
- Third Rock Ventures GP VI, L.P. (entity) · since Oct 24, 2024
- Third Rock Ventures V, L.P. (entity) · since Oct 24, 2024
- Third Rock Ventures VI, L.P. (entity) · since Oct 24, 2024
- Trv Gp V, LLC (entity) · since Oct 24, 2024
- Trv Gp Vi, LLC (entity) · since Oct 24, 2024
Changes in the last 10 years (35)
| Aug 24, 2026 | Rajiv Patni became Chief Medical Officer |
| Jan 5, 2026 | Mark Andrew Wilson became Chief Legal Officer |
| Sep 25, 2025 | Keith Michael Gottesdiener became a director |
| Aug 11, 2025 | Jeffrey Finer listed as Chief Executive Officer (previously CEO and President) in SEC filings |
| Aug 11, 2025 | Elizabeth Bhatt listed as President and COO (previously Chief Operating Officer) in SEC filings |
| Jan 6, 2025 | Gil M Labrucherie became Chief Financial Officer |
| Oct 24, 2024 | Uwe Klein became SVP, Biological Sciences |
| Oct 24, 2024 | Trv Gp Vi, LLC became a 10% owner |
| Oct 24, 2024 | Trv Gp V, LLC became a 10% owner |
| Oct 24, 2024 | Third Rock Ventures VI, L.P. became a 10% owner |
| Oct 24, 2024 | Third Rock Ventures V, L.P. became a 10% owner |
| Oct 24, 2024 | Third Rock Ventures GP VI, L.P. became a 10% owner |
| Oct 24, 2024 | Third Rock Ventures GP V, LP became a 10% owner |
| Oct 24, 2024 | Shalini Sharp became a director |
| Oct 24, 2024 | Samira Shaikhly became Chief People Officer |
| Oct 24, 2024 | Ran Xiao became Interim CFO |
| Oct 24, 2024 | Rajeev M. Shah became a director |
| Oct 24, 2024 | Rajeev M. Shah became a 10% owner |
| Oct 24, 2024 | Ra Capital Management, L.p. became a director |
| Oct 24, 2024 | Ra Capital Management, L.p. became a 10% owner |
| Oct 24, 2024 | RA Capital Nexus Fund III, L.P. became a director |
| Oct 24, 2024 | RA Capital Healthcare Fund LP became a director |
| Oct 24, 2024 | RA Capital Healthcare Fund LP became a 10% owner |
| Oct 24, 2024 | Peter Kolchinsky became a director |
| Oct 24, 2024 | Peter Kolchinsky became a 10% owner |
| Oct 24, 2024 | Jeffrey K Tong became a director |
| Oct 24, 2024 | Jeffrey Finer became a director |
| Oct 24, 2024 | Jeffrey Finer became CEO and President |
| Oct 24, 2024 | Jake Simson became a director |
| Oct 24, 2024 | Jae B. Kim became Chief Medical Officer |
| Oct 24, 2024 | Elizabeth Bhatt became Chief Operating Officer |
| Oct 24, 2024 | Daniel D. Long became SVP, Drug Discovery |
| Oct 24, 2024 | Bernard Coulie became a director |
| Oct 24, 2024 | Alan Ezekowitz became a director |
| Oct 24, 2024 | Abraham Bassan became a director |
Not reported recently (1)
- Ran Xiao · Last reported as Interim CFO in an SEC filing dated Oct 24, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SEPN Proposed Insider Sales (Form 144)
Latest: 2026-10-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
6 filings
· $81.5M notice value
· 6 unique filers
· 67% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
RA Capital Healthcare Fund LP (1, $36.0M) · RA Capital Nexus Fund III, L.P. (1, $36.0M) · Third Rock Ventures V, L.P. (1, $7.5M) · ELIZABETH P. BHATT (1, $1.1M) · SAMIRA SHAIKHLY (1, $493K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-01 | DANIEL LONG | Officer | 10,001 | $391.3K | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-01 | SAMIRA SHAIKHLY | Officer | 12,592 | $492.7K | 2026-10-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-12 | Third Rock Ventures V, L.P. | 10% Stockholder | 147,200 | $7.51M | 2026-08-12 | Raymond James & Associates | 10b5-1 | EDGAR |
| 2026-08-12 | RA Capital Healthcare Fund LP | affiliate | 746,500 | $35.97M | 2026-08-12 | BTIG LLC | — | EDGAR |
| 2026-08-12 | RA Capital Nexus Fund III, L.P. | Affiliate | 746,500 | $35.97M | 2026-08-12 | BTIG LLC | — | EDGAR |
| 2026-08-11 | ELIZABETH P. BHATT | Officer | 29,000 | $1.13M | 2026-08-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-15 | ELIZABETH P. BHATT | Officer | 4,000 | $138.2K | 2026-07-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-26 | JAE KIM | Officer | 2,438 | $89.2K | 2026-06-26 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-22 | DANIEL LONG | Officer | 25,000 | $904.2K | 2026-06-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-22 | JAE KIM | Officer | 94,339 | $3.33M | 2026-06-22 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-10 | 0001193125-26-342353 | EDGAR |
ETF Holders
63 ETFs hold SEPN
25 shown · $159.27M total exposure · 0.04% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $41.3M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.04% | $27.9M | $76.6B | 2026-11-06 |
| 3 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 2.48% | $11.5M | $466.5M | 2026-11-05 |
| 4 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.10% | $10.8M | $11.1B | 2026-11-06 |
| 5 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.82% | $10.8M | $1.3B | 2026-11-06 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $10.5M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.05% | $6.9M | $13.7B | 2026-11-06 |
| 8 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.39% | $5.3M | $1.4B | 2026-11-06 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $5.0M | — | 2026-09-30 |
| 10 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.2M | — | 2026-08-31 |
| 11 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 0.25% | $3.9M | $1.7B | 2026-11-06 |
| 12 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $3.4M | $13.9B | 2026-11-06 |
| 13 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.10% | $3.0M | $3.2B | 2026-11-05 |
| 14 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.13% | $2.3M | — | 2026-11-05 |
| 15 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.0M | — | 2026-09-30 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $1.9M | — | 2026-11-05 |
| 17 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.5M | $93.2B | 2026-11-06 |
| 18 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.4M | — | 2026-11-05 |
| 19 | JPSE JPMorgan Diversified Return U.S. Small Cap Equity ETF | JPMorgan | 0.18% | $988,040 | $560.5M | 2026-11-06 |
| 20 | FAD First Trust Multi Cap Growth AlphaDEX® Fund | First Trust | 0.17% | $969,868 | $570.9M | 2026-11-06 |
| 21 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $880,189 | — | 2026-11-05 |
| 22 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $835,112 | $10.0B | 2026-11-05 |
| 23 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.07% | $752,912 | $1.0B | 2026-11-05 |
| 24 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.04% | $623,654 | — | 2026-09-30 |
| 25 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.16% | $582,207 | — | 2026-08-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.55
TTM Revenue
$98.88M
TTM Net Income
$-24.24M
TTM Op. Cash Flow
$106.01M
Quarterly figures (7 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $26.75M | $-13.03M | $-0.29 | $-22.18M |
| Q1 '26 | 2026-03-31 | $26.52M | $-8.64M | $-0.19 | $-25.63M |
| Q4 '25 | 2025-12-31 | $24.12M | $-10.74M | $-0.24 | $-14.99M |
| Q3 '25 | 2025-09-30 | $21.50M | $8.17M | $0.18 | $168.81M |
| Q2 '25 | 2025-06-30 | $119.00K | $-24.84M | $-0.56 | $-20.29M |
| Q1 '25 | 2025-03-31 | $219.00K | $-21.48M | $-0.49 | $-23.34M |
| Q4 '24 | 2024-12-31 | $212.00K | $-20.67M | $14.61 | $-20.96M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
5.72
P/S
22.38
EV/EBITDA
—
EV/Sales
21.53
ROE
-6.3%
ROA
-4.3%
Div Yield
0.00%
FCF Yield
4.79%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.21B
as of 2026-11-09
SEPN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.9 | +7.8% | +36.2% | 58 |
| ZTS ZOETIS INC. | $32.3B | 13.6 | +2.6% | −34.7% | 9 |
| RPRX Royalty Pharma plc Class A Ordinary Shar | $30.0B | 48.8 | +11.4% | +77.2% | 38 |
| VTRS Viatris Inc. Common Stock | $22.8B | — | +4.3% | +64.5% | 43 |
| MANE Veradermics, Incorporated | $5.8B | — | — | +283.1% | 1 |
| XERS Xeris Biopharma Holdings, Inc. Common St | $2.8B | — | +38.4% | +114.7% | 15 |
| SEPN Septerna, Inc. Common Stock | $2.3B | — | +13520.1% | +76.9% | 36 |
| SUPN Supernus, Inc. Common Stock | $1.5B | — | +26.9% | −44.0% | 11 |
| Peer median | $26.4B | 44.5 | +11.4% | +50.3% | 21 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.52M
SI % of Float
12.04%
Days to Cover
7.63
Short Vol Ratio
58.6%
Free Float
29.25M
Float %
62.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14